Romiplostim Trial Offers Hope for Chemotherapy-Induced Thrombocytopenia

A global Phase 3 clinical trial, spearheaded by investigators at Mass General Brigham, has unveiled a significant breakthrough in cancer care: the medication romiplostim can effectively prevent chemotherapy-induced thrombocytopenia. This common and challenging condition occurs when chemotherapy damages the bone marrow cells responsible for producing platelets.

Romiplostim's mechanism is crucial for patient well-being, as it actively enhances the bone marrow's ability to produce platelets, which are essential for preventing dangerous bleeding.

The findings, published in the New England Journal of Medicine, address a pervasive complication in cancer treatment.

Dr. Hanny Al-Samkari, lead author and a hematologist at Mass General Brigham Cancer Institute, highlighted the current unmet need: "There are currently no approved medications for chemotherapy-induced thrombocytopenia, which significantly elevates the risk of major or life-threatening bleeding."

Oncologists often resort to reducing or delaying chemotherapy doses to manage this condition. Studies indicate that these dose modifications can negatively impact cancer treatment outcomes, including overall survival.

Dr. Al-Samkari expressed optimism that romiplostim's potential to enable the administration of full-dose, on-time chemotherapy is hoped to translate into longer patient survival.

The RECITE Trial: Key Findings

The RECITE trial enrolled 165 patients suffering from advanced colorectal, gastroesophageal, or pancreatic cancer. Patients were divided into two groups: 109 received romiplostim, while 56 were assigned to a placebo.

The results demonstrated a stark difference:

• Patients receiving romiplostim had over 10 times lower odds of requiring chemotherapy dose reductions due to thrombocytopenia.
• Specifically, 84% of patients in the romiplostim group did not experience chemotherapy dose modifications, a stark contrast to only 36% in the placebo group.

Adverse Events Profile

Adverse events of grade 3 or higher were reported in 37% of patients who received romiplostim and in 22% of those who received placebo. These more severe events were primarily attributed to the multiagent chemotherapy itself and the higher chemotherapy doses tolerated by patients in the romiplostim group.

Adverse events directly related to romiplostim or placebo were less frequent, observed in 12% of the romiplostim group and 7% of the placebo group. The most common of these were:

• Nausea (2% in each group)
• Headache (2% in the romiplostim group)

Crucially, no serious adverse events, deaths, or discontinuations of romiplostim, placebo, or chemotherapy were linked to these specific adverse events. Clotting-related adverse events were reported in 2% of patients taking romiplostim and in no patients taking placebo.